title: [New anticoagulants in the treatment of venous thromboembolism].
abstract: Anticoagulant therapy is the cornerstone of treatment of venous thromboembolism (VTE). The treatment needs rapid initial anticoagulaton to minimize the risk of thrombus extension and fata pulmonary embolism, followed by an extended anticoagulation, aimed at preventing recurrent VTE. Till very recently, immediate anticoagulation can only be achieved with parenteral agents, such as heparin, low-molecular-weight heparin, or fondaparinux. Extended treatment usually involves the administration of vitamin K antagonists, such as warfarin. Emerging direct oral anticoagulants have the potential to streamline VTE treatment. These agents include oral anticoagulants that target thrombin or factor Xa. This article reviews the characteristics of these agents, describes the results of clinical trials in venous thromboembolic disease and outlines their strengths and weakness.
authors.affiliation: Service de médecine vasculaire, centre hospitalo-universitaire de Toulouse, faculté de médecine, université Paul-Sabatier, 31 059 Toulouse Cedex 9, France. bura-riviere.a@chu-toulouse.fr
authors.forename: Alessandra
authors.initials: A
authors.lastname: Bura-Rivière
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D011720:Pyrazoles / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D054556:Venous Thromboembolism / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban